StreetInsider.com News Articles

Form 8-K/A Amneal Pharmaceuticals, For: Aug 10

Fri, 23 Oct 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20261023/27227889.html

Amneal Pharmaceuticals (AMRX) PT Raised to $24 at JPMorgan

Thu, 22 Oct 2026 08:53:05 -0400

JPMorgan analyst Chris Schott raised the price target on Amneal Pharmaceuticals (NASDAQ: AMRX) to $24.00 (from $22.00) while maintaining a Overweight rating.

Amneal to Report Third Quarter 2026 Results on November 3, 2026

Thu, 08 Oct 2026 08:00:00 -0400

BRIDGEWATER, N.J., Oct. 08, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) (“Amneal” or the “Company”), today announced it will report third quarter 2026 financial results on Tuesday, November 3, 2026, before market open. The Company will host an audio webcast at 8:30 a.m. ET.

The financial results and live webcast will be available through the Investor Relations section of the Company's website at investors.amneal.com. Individuals may register for the webcast by clicking here. To access the call by phone, dial 1 (833) 461-5787 (U.S.) or view a list of toll-free international

Amneal to Report Third Quarter 2026 Results on November 3, 2026

Thu, 08 Oct 2026 08:00:00 -0400

UBS Reiterates Buy Rating on Amneal Pharmaceuticals (AMRX)

Thu, 01 Oct 2026 09:16:08 -0400

UBS analyst Ashwani Verma reiterated a Buy rating and $25.00 price target on Amneal Pharmaceuticals (NASDAQ: AMRX).

The analyst commented, "Mgmt views the HRT patch franchise as a key near term value driver that remains underappreciated by investors. The opportunity could be 4-5x larger than the current market, with patch penetration among menopausal women projected to increase from ~5% today to 30-40% over time. Following a recent manufacturing expansion that quadrupled capacity, AMRX currently supplies (or has the capacity to supply) ~30% of the market and plans further capacity additions to maximize supply and share gains."

For an analyst ratings summary and

Oppenheimer Starts Amneal Pharmaceuticals (AMRX) at Outperform

Wed, 23 Sep 2026 06:12:37 -0400

Oppenheimer analyst Les Sulewski initiates coverage on Amneal Pharmaceuticals (NASDAQ: AMRX) with a Outperform rating and a price target of $27.00.

The analyst comments "We initiate coverage of Amneal Pharmaceuticals with an Outperform rating and $27 PT. We believe AMRX is at a fundamental inflection as differentiated launches, vertically integrated biosimilars, and Specialty growth reshape its earnings profile. The $750M Kashiv acquisition creates a scaled biosimilars platform targeting $1B-$1.3B of revenue by 2030, and Crexont, Brekiya, and recently launched Lanreotide provide multiple near-term growth drivers. Longer term, the Pfizer/Metsera collaboration adds GLP-1 manufacturing and emerging-market optionality. We expect improving mix and

Oppenheimer Starts Amneal Pharmaceuticals (AMRX) at Outperform

Wed, 23 Sep 2026 06:12:37 -0400

Oppenheimer analyst Les Sulewski initiates coverage on Amneal Pharmaceuticals (NASDAQ: AMRX) with a Outperform rating and a price target of $27.00.

Form 4 Amneal Pharmaceuticals, For: Sep 11 Filed by: BUCHI J KEVIN

Tue, 22 Sep 2026 17:10:00 -0400

si-local-file:///var/storage/secattach/20260922/27091855.html

Form 4 Amneal Pharmaceuticals, For: Sep 17 Filed by: BUCHI J KEVIN

Mon, 21 Sep 2026 16:36:00 -0400

si-local-file:///var/storage/secattach/20260921/27085750.html

Amneal gets FDA approval for lanreotide injection, launches immediately

Fri, 18 Sep 2026 16:01:10 -0400

Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) announced that the U.S. Food and Drug Administration has approved its lanreotide injection, 120 mg/0.5 mL, in a sterile, single-dose prefilled syringe. The Bridgewater, N.J.-based company said it launched the product immediately following approval.

The product references Somatuline Depot, a registered trademark of Ipsen Pharma S.A.S., and received Competitive Generic Therapy designation from the FDA. U.S. annual sales of Somatuline Depot totaled $983 million for the 12 months ended July 2026, according to IQVIA.

Lanreotide injection is indicated for the treatment of acromegaly, advanced gastro-enteropancreatic neuroendocrine tumors, and carcinoid syndrome. The product is manufactured in-house by Amneal.

"Lanreotide

Amneal Announces FDA Approval and Launch of Lanreotide Injection

Fri, 18 Sep 2026 16:01:00 -0400

- Expands complex injectables portfolio with important long-acting oncology treatment
- Immediate commercial launch supported by in-house production

BRIDGEWATER, N.J., Sept. 18, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) (NASDAQ: AMRX) today announced that the U.S. Food and Drug Administration (FDA) has approved its lanreotide injection, 120 mg/0.5 mL, in a sterile, single-dose prefilled syringe. The product references SOMATULINE^® Depot and will launch immediately. The product received Competitive Generic Therapy (CGT) designation from the FDA.

“The approval and launch of lanreotide adds another material growth driver to our Affordable Medicines business,”

Amneal Announces FDA Approval and Launch of Lanreotide Injection

Fri, 18 Sep 2026 16:01:00 -0400

- Expands complex injectables portfolio with important long-acting oncology treatment
- Immediate commercial launch supported by in-house production

“The approval and launch of lanreotide adds another material growth driver to our Affordable Medicines business,”

Amneal Pharmaceuticals (AMRX) PT Raised to $20 at Barclays

Thu, 17 Sep 2026 04:35:03 -0400

Barclays analyst Glen Santangelo raised the price target on Amneal Pharmaceuticals (NASDAQ: AMRX) to $20.00 (from $16.00) while maintaining a Overweight rating.

Form 4 Amneal Pharmaceuticals, For: Sep 11 Filed by: BUCHI J KEVIN

Mon, 14 Sep 2026 16:10:00 -0400

si-local-file:///var/storage/secattach/20260914/27058497.html

Leerink Starts Amneal Pharmaceuticals (AMRX) at Outperform

Wed, 09 Sep 2026 06:11:30 -0400

Leerink analyst Daniel Clark initiates coverage on Amneal Pharmaceuticals (NASDAQ: AMRX) with a Outperform rating and a price target of $23.00.

For an analyst ratings summary and ratings history on Amneal Pharmaceuticals click here. For more ratings news on Amneal Pharmaceuticals click here.

Shares of Amneal Pharmaceuticals closed at $17.05 yesterday.

Form 4 Amneal Pharmaceuticals, For: Aug 21 Filed by: BOYER ANDREW S

Tue, 25 Aug 2026 16:42:00 -0400

si-local-file:///var/storage/secattach/20260825/26975301.html

Form 4 Amneal Pharmaceuticals, For: Aug 21 Filed by: BOYER ANDREW S

Tue, 25 Aug 2026 16:42:00 -0400

si-local-file:///var/storage/secattach/20260825/26975301.html

DA Davidson Starts Amneal Pharmaceuticals (AMRX) at Neutral

Mon, 24 Aug 2026 16:23:07 -0400

DA Davidson analyst Garik Shmois initiates coverage on Amneal Pharmaceuticals (NASDAQ: AMRX) with a Neutral rating.

For an analyst ratings summary and ratings history on Amneal Pharmaceuticals click here. For more ratings news on Amneal Pharmaceuticals click here.

Shares of Amneal Pharmaceuticals closed at $17.91 yesterday.

Form 4 Amneal Pharmaceuticals, For: Aug 13 Filed by: Kiely John

Fri, 14 Aug 2026 16:32:00 -0400

si-local-file:///var/storage/secattach/20260814/26931459.html

Form 4 Amneal Pharmaceuticals, For: Aug 13 Filed by: Kiely John

Fri, 14 Aug 2026 16:32:00 -0400

si-local-file:///var/storage/secattach/20260814/26931459.html

Form 4 Amneal Pharmaceuticals, For: Aug 11 Filed by: Daly Jason B.

Thu, 13 Aug 2026 16:22:00 -0400

si-local-file:///var/storage/secattach/20260813/26921594.html

Form 4 Amneal Pharmaceuticals, For: Aug 11 Filed by: Daly Jason B.

Thu, 13 Aug 2026 16:22:00 -0400

si-local-file:///var/storage/secattach/20260813/26921594.html

Form 4 Amneal Pharmaceuticals, For: Aug 12 Filed by: Shah Nikita

Thu, 13 Aug 2026 16:22:00 -0400

si-local-file:///var/storage/secattach/20260813/26921602.html

Form 4 Amneal Pharmaceuticals, For: Aug 12 Filed by: Shah Nikita

Thu, 13 Aug 2026 16:22:00 -0400

si-local-file:///var/storage/secattach/20260813/26921602.html

Form 4 Amneal Pharmaceuticals, For: Aug 11 Filed by: BUCHI J KEVIN

Thu, 13 Aug 2026 16:21:00 -0400

si-local-file:///var/storage/secattach/20260813/26921578.html